Cytori Cell Research Institute, Inc. (TYO:3750)
Japan
· Delayed Price · Currency is JPY 692.00
-6.00 (-0.86%)
May 23, 2025, 3:30 PM JST
TYO:3750 Revenue
In the fiscal year ending March 31, 2025, Cytori Cell Research Institute had annual revenue of 122.00M JPY, down -92.18%. Cytori Cell Research Institute had revenue of 7.00M in the quarter ending March 31, 2025, a decrease of -95.30%.
Revenue
122.00M
Revenue Growth
-92.18%
P/S Ratio
50.64
Revenue / Employee
7.63M
Employees
16
Market Cap
6.18B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 122.00M | -1.44B | -92.18% |
| Mar 31, 2024 | 1.56B | -584.00M | -27.24% |
| Mar 31, 2023 | 2.14B | 809.00M | 60.60% |
| Mar 31, 2022 | 1.34B | -53.00M | -3.82% |
| Mar 31, 2021 | 1.39B | 208.00M | 17.63% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chugai Pharmaceutical | 1,222.12B |
| Daiichi Sankyo Company | 1,886.26B |
| Takeda Pharmaceutical Company | 4,581.55B |
| HOYA Corporation | 869.37B |
| Terumo | 1,036.17B |
| Otsuka Holdings | 2,393.18B |
| Astellas Pharma | 1,912.32B |
| Olympus | 997.33B |